AEterna Zentaris: Perifosine offers partial response in 43% of renal cell carcinoma patients

By Elaine Rigoli

Tampa, Fla., June 5 - AEterna Zentaris, Inc.'s released data for perifosine (KRX-0401) in patients with advanced renal cell carcinoma (RCC) and disclosed phase 1 results for its cytotoxic conjugate AN-152 in patients with gynecological and breast cancers.

Thirteen patients with RCC were enrolled in the perifosine study, and of those, seven were evaluable for response.

Of the seven patients, three, or 43%, had a partial response and two patients, or 29%, achieved long-term stable disease.

These patients, part of a phase 2, multi-center trial of perifosine that included multiple tumor types, had prior standard therapy, according to a news release.

Two progressed, the release said, while four patients were inevaluable because they stopped treatment early and their disease was not evaluated at the time drug was stopped.

Further, two patients have not been on the study long enough to reach the first point of evaluation.

AEterna Zentaris also said its cytotoxic conjugate AN-152 in patients with gynecological and breast cancers showed that the compound has a good safety profile and no dose-limiting toxicities.

Eight patients entered the study and received AN-152 by intravenous infusion over two hours at dosages of 10, 20, 40, 80, 160 and 267 mg, the release said.

Stabilization of disease was observed in one of the eight patients in the ongoing phase 1 study.

AN-152 is in a phase 1 trial in breast, endometrial and ovarian cancers.

AEterna Zentaris is a global biopharmaceutical company located in Quebec City, Quebec.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.